- Report
- February 2026
- 250 Pages
Global
From €3995EUR$4,490USD£3,430GBP
- Report
- September 2026
- 192 Pages
Global
From €3154EUR$3,545USD£2,708GBP
€3505EUR$3,939USD£3,009GBP
- Report
- September 2026
- 485 Pages
Global
From €5206EUR$5,850USD£4,469GBP
- Report
- September 2026
- 483 Pages
Global
From €5206EUR$5,850USD£4,469GBP
- Report
- September 2026
- 377 Pages
Global
From €5206EUR$5,850USD£4,469GBP
- Report
- February 2026
- 250 Pages
Global
From €3995EUR$4,490USD£3,430GBP
- Report
- January 2026
- 186 Pages
Global
From €4004EUR$4,500USD£3,437GBP
- Report
- July 2026
- 200 Pages
Global
From €7110EUR$7,990USD£6,103GBP
- Report
- July 2026
- 395 Pages
Global
From €7110EUR$7,990USD£6,103GBP
- Report
- August 2026
- 120 Pages
Global
From €4227EUR$4,750USD£3,628GBP
- Report
- November 2025
- 196 Pages
Global
From €4405EUR$4,950USD£3,781GBP
- Report
- June 2025
- 200 Pages
United States
From €2216EUR$2,490USD£1,902GBP
- Report
- August 2022
- 115 Pages
Global
From €4004EUR$4,500USD£3,437GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2225EUR$2,500USD£1,910GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1112EUR$1,250USD£955GBP
- Report
- August 2024
- 233 Pages
Global
From €7074EUR$7,950USD£6,073GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2482EUR$2,789USD£2,130GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2482EUR$2,789USD£2,130GBP
- Report
- May 2024
- 132 Pages
Global
From €2669EUR$2,999USD£2,291GBP
€3558EUR$3,999USD£3,055GBP
- Report
- May 2024
- 138 Pages
Global
From €2669EUR$2,999USD£2,291GBP
€3558EUR$3,999USD£3,055GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more